Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation

The purpose of this study is to evaluate the consistency of quantitative peak stress myocardial blood flow and myocardial blood flow reserve following a 10 second, 1 minute, 2 minute or 4 minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection. It is anticipated that there will be no or minimal difference between the four delay times.

Inclusion Criteria:

• Recent normal clinically-indicated exercise myocardial perfusion SPECT, treadmill maximal exercise test or exercise echocardiographic study
• No change in symptoms between the exercise study and PET study
• Capable of providing written informed consent
• BMI 25-32 kg/m2

Exclusion Criteria:

• Diabetes mellitus
• Coronary Artery Calcium Score >25
• Second and Third Degree Atrioventricular Node Block
• Sinus Node Dysfunction
• Recent Syncope of unknown etiology
• Left ventricular hypertrophy per ECG or echocardiography
• Slowed circulation times
• Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes in therapy within the past 30 days.
• Patients that have experienced a previous hypersensitivity reaction thought to be related to Lexiscan